Introduced in December 2025, Oral Wegovy includes the same GLP-1 mechanism that Wegovy injections use, offering flexibility and effectiveness in managing weight
Critical questions remain regarding the optimal timing of tirzepatide initiation, dose optimization strategies, and potential synergistic effects with standard therapies
Research consistently shows that only 5 to 10% of people who lose significant weight through diet and exercise alone maintain that loss long-term
NAD+: Enhances mitochondrial function, reduces oxidative stress, and supports cartilage integrity
Abstract Background Prescribing information instructs taking oral semaglutide (a glucagon-like peptide-1 analogue) in the fasting state, followed by a post-dose fasting period of 30 min
The most consequential pending readout is TRANSCEND-T2D-2, the head-to-head trial pitting retatrutide against semaglutide in type 2 diabetes over 80 weeks